Left ventricular deformation and torsion assessed by speckle-tracking echocardiography in patients with mutated transthyretin-associated cardiac amyloidosis and the effect of diflunisal on myocardial function  by Koyama, Jun et al.
IJC Heart & Vasculature 9 (2015) 1–10
Contents lists available at ScienceDirect
IJC Heart & Vasculature
j ou rna l homepage: ht tp : / /www. journa ls .e lsev ie r .com/ i jc -hear t -and-vascu la tureLeft ventricular deformation and torsion assessed by speckle-tracking
echocardiography in patients with mutated transthyretin-associated
cardiac amyloidosis and the effect of diﬂunisal on myocardial function☆Jun Koyama a,⁎, Masatoshi Minamisawa a, Yoshiki Sekijima b, Shu-ichi Ikeda b, Ayako Kozuka a,
Soichirou Ebisawa a, Takashi Miura a, Hirohiko Motoki a, Ayako Okada a, Atsushi Izawa a, Uichi Ikeda a
a Department of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto, Japan
b Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan☆ There is no relationship with industry to disclose.
⁎ Corresponding author at: Department of Cardiovascul
School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390
E-mail address: jkoyama@shinshu-u.ac.jp (J. Koyama)
http://dx.doi.org/10.1016/j.ijcha.2015.07.010
2352-9067/© 2015 The Authors. Published by Elsevier Irea b s t r a c ta r t i c l e i n f oArticle history:
Received 18 May 2015
Received in revised form 29 July 2015
Accepted 30 July 2015
Available online 4 August 2015
Keywords:
Mutated transthyretin
Cardiac amyloidosis
Speckle tracking echocardiography
Strain
Background: Mutated transthyretin-associated (ATTRm) amyloidosis with heart failure is associated with
decreased longitudinal left ventricular (LV)myocardial contraction, as measured by strain Doppler echocardiog-
raphy.We sought to clarify whether speckle-tracking echocardiography (STE) would provide useful information
in patients with ATTRm cardiac amyloidosis.
Methods: One hundred twenty-three consecutive patients with ATTRm amyloidosis were divided into 3 groups.
Group 1 had no evidence of cardiac involvement (n = 47), group 2 had heart involvement but no congestive
heart failure (CHF) and/or serum brain natriuretic peptide (BNP) levels b100 pg/mL (n = 35), and group 3
had heart involvement and CHF and/or serum BNP levels ≥100 pg/mL (n=41). All patients underwent standard
2-dimensional (2D), Doppler echo, and STE.
Results: By standard 2D and Doppler echo, differences in parameters were only apparent between group 3 and
groups 1 and 2. Global circumferential strains by STE at each LV level and LV torsion were different between
group 1 and groups 2 and 3, but not between group 2 and group 3. In contrast, global longitudinal LV strain showed
signiﬁcant intergroup differences (−17.3 ± 2.3%,−13.3 ± 2.3%,−9.9 ± 3.3% for groups 1 to 3, respectively, P b
0.0001). Radial strain also showed signiﬁcant intergroup differences for each basal LV segment. Among 41 patients
who couldhave been followedup after 1 year, 34 patientswith diﬂunisal treatment had shown improvement in api-
cal rotation and torsion without deterioration in multidirectional strains.
Conclusion: ATTRm cardiac amyloidosis is characterized by progressive impairment in longitudinal and basal LV ra-
dial function when global circumferential shortening and torsion remain unchanged.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. IntroductionCardiac amyloidosis is a cardiomyopathy associated with thickening
of all 4 chambers, with biatrial dilation, a normal or mildly dilated right
ventricle, and normal or decreased left ventricular (LV) cavity size.
Congestive heart failure (CHF) may occur even if LV ejection fraction is
normal [1–7]. Therefore, it is generally considered that CHF in cardiac
amyloidosis manifests predominantly as diastolic LV dysfunction, with
systolic dysfunction only occurring late in the disease [5,8–12]. Tissue
Doppler echocardiography has demonstrated that cardiac amyloidosis
is characterized by early impairment of systolic function at a time
when fractional shortening remains normal, and that this abnormality
precedes the onset of CHF [13,14]. Speckle tracking echocardiographyarMedicine, Shinshu University
-8621, Japan.
.
land Ltd. This is an open access articl(STE) allows the evaluation of different components of complex cardiac
motions, such as longitudinal, circumferential, and radial strain, and
rotation [15–18].
Many studies have focused on light-chain associated cardiac amy-
loidosis, but few data concerning mutated transthyretin-associated
(ATTRm) amyloidosis have been derived using strain echocardiography
[19–21]. The purpose of this study was to clarify whether STE could
detect early regionalmyocardial dysfunction in ATTRm amyloidosis, be-
fore the onset of CHF, and to determine whether change in regional
myocardial deformation can be detected by STE in these patients after
oral small-molecule treatment by diﬂunisal [20].
2. Methods
2.1. Study population
One hundred twenty-eight consecutive patients with ATTRm amy-
loidosis were examined at the Shinshu University Hospital betweene under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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by biopsy of involved organs, which demonstrated the typical Congo-
red birefringence when viewed under polarized light. ATTRm amyloid-
osis was diagnosed from amyloid deposition in the abdominal fat
pad (n = 90), endocardium (n = 10), stomach (n = 6), duodenum
(n=5), and rectum (n=7), skin (n= 4), sural nerve (n= 4), vitreum
(n=3), and from the biopsy of carpal tunnel (n=1) (there are overlap
in some patients). Additionally, TTR gene analysis was routinely carried
out, as previously described [22,23].Patients with atrial ﬁbrillation
(n = 5) were not included. Thus the ﬁnal population consisted of
123 patients.
All patients underwent a physical examination by cardiologists,
with particular emphasis on the signs and symptoms of CHF, or a
chest radiographic appearance of heart failure and/or the presence of
elevated jugular venous pressure with peripheral edema [13,14,24–
26]. Echocardiograms were reviewed by 2 readers to determine the
degree of cardiac involvement, deﬁned as a mean LV wall thickness
N12 mm in the absence of hypertension, valvular heart disease, or
criteria for LV hypertrophy on the electrocardiogram [6,7,13,14,
24–26]. Some patients, who were not indicated for liver transplan-
tation (n = 41), had been prescribed diﬂunisal, which prevents
amyloidogenesis in vitro [27], and these patients were examined before
and 1 year after starting themedication. Of these 41 patients, 7 patients
discontinued diﬂunisal administration because of transient acute dete-
rioration of renal function. Plasma levels of brain natriuretic peptide
(BNP) were measured on the day of echocardiography, as previously
described [28].
Seventy-six patients met the echocardiographic criteria for cardiac
involvement, and 47 had no features of cardiac amyloidosis. The latter
group was deﬁned as group 1 (noncardiac amyloid), as we described
previously [13,14,24–26]. Some patients with ATTRm had gait impair-
ment due to peripheral nerve neuropathy, which limits behavior
and masks CHF symptoms. In such patients, plasma BNP levels ≥100
pg/mL were taken as the criterion for CHF. Of the 76 patients with car-
diac amyloidosis, 41 had prior or current evidence of CHF or plasma
BNP levels ≥100 pg/mL [29]. These patients were deﬁned as group 3
(CHF [+]), and the remaining 35 were deﬁned as group 2 (CHF [−]).
Positive ﬁndings of 99mTc-PYP accumulation in the heart were also
used to deﬁne groups 2 and 3 (cardiac amyloid).
2.2. Standard echocardiography
Ultrasound examinations were performed using a Vivid 7 System
echocardiograph (General Electric Healthcare, Milwaukee, WI, USA)
with a 1.5–4.0 MHz (M3S) transducer. Standard M-mode measure-
ments of the LV were made. The LV end-diastolic and end-systolic vol-
umes, ejection fraction, and left atrial (LA) maximum and minimum
volumes were measured as previously described [30]. Transmitral, pul-
monary venous, and LV outﬂow tract ﬂow velocities were measured by
pulsed Doppler echocardiography as previously described [13,14,24,
26–30]. Pulsed tissue Doppler imaging was performed using harmonic
imaging, and the gate length of regions of interest was set at 0.59 cm.
Sample volumes were placed on the basal interventricular septum and
basal lateral walls, as described previously [13].
2.3. Speckle tracking echocardiography
Two-dimensional black-and-white cardiac cycle acquisitions were
recorded in apical 2-chamber and 4-chamber views, apical long-axis
view, and parasternal short-axis view (at base, mid, and apex), and
stored on a hard drive. Three consecutive beats were stored in each
view during breath-hold at a frame rate of 70–97 frames/s. Speckle-
tracking analysis was performed ofﬂine by commercially available
software (Echo Pac PC ver. 112; GE Vingmed Ultrasound, AS, Horten,
Norway). After manual tracing of the endocardial border at end systole
for apical and short-axis views, a region of interest was manuallyadjusted to include the entire myocardial thickness. The LV global and
segmental longitudinal 2-dimensional strains were assessed in the
apical 2-chamber, 4-chamber, and long-axis views by automated func-
tion imaging. Global and segmental longitudinal strain rates were mea-
sured from 3 apical views, and the values were averaged. LV global
circumferential strain (GCS) and strain rate were measured in the
parasternal short-axis view at basal, mid, and apical LV.
Segmental circumferential strain, strain rate, LV radial strain (RS),
and strain rate were calculated for 6 segments (anteroseptal, anterior,
lateral, posterior, inferior, and septal walls) in the parasternal short-
axis view at basal, mid, and apical LV.
Measurement of LV rotation and torsionwas performed as previously
described [18].
Peak systolic LV torsion was calculated as the maximum instanta-
neous difference between peak systolic apical and basal rotation, using
the R-peak in the electrocardiogram as a reference point. For LV torsion
rate, the peak systolic, peak early diastolic, and peak late diastolic values
were measured. In the follow-up echocardiographic assessment 1 year
after the initial examination, each echocardiographicmoviewas record-
ed at the same frame rate, depth, and cut plane as with the previous
picture.
2.4. Intraobserver and interobserver reproducibilities
To test the intraobserver reproducibility of the strain, strain rate,
rotation, and torsion variables, 20 randomly selected patients were
reviewed by the same observer N2 weeks after the ﬁrst measurements.
To test interobserver reproducibility, measurements were repeated by
a second observer. The bias (mean difference) and limits of agreement
between the ﬁrst and second measurements were determined. To
assess [18] reproducibility, the coefﬁcient of variation was calculated
as the standard deviation of the difference divided by the mean.
2.5. Statistical analyses
The normal distribution of continuous variables was checked using
the Shapiro–Wilk W test, and all data were then expressed as mean ±
standard deviation (SD). Categorical variables were expressed as abso-
lute numbers and percentages. Statistical analyses were performed
using commercially available software (JMP 9.0.2, SAS Institute, Cary,
North Carolina, and Graph Pad Prism 5 for Mac OS X, GraphPad, San
Diego, California, USA). Differences among the 3 groups were assessed
using one-way analysis of variance, with Tukey–Kramer's HSD test for
parametric variables, the Kruskal–Wallis test with Dunn's post-hoc
test for nonparametric variables, and the chi-square test for categorical
variables. The Bland–Altman analysis was conducted to assess intra-
and interobserver agreements (expressed as absolute value of mean
difference±1.96 SD), and intraclass correlation coefﬁcientswere calcu-
lated. Follow-up datawere tested by paired t test in each group. A differ-
ence or correlation was considered signiﬁcant when the probability
value was b0.05.
This study was approved by the Ethics Committee of the Shinshu
University School of Medicine and written informed consent was ob-
tained from each patient.
3. Results
3.1. Patients' characteristics
The clinical characteristics are shown in Table 1. The agewas greater
in groups 2 and 3 compared to group 1. There were more men in group
2 than the other 2 groups. Most patients (92.7%) which entered this
study had the same transthyretin mutation, involving the substitution
of methionine for valine at position 30 (V30M). Other types ofmutation
were summarized in Table 1. Diastolic blood pressure was lower in
group 3 than that in the other 2 groups. Heart rate in groups 2 and 3
Table 1
Clinical and echocardiographic characteristics of the patients in this study (n = 123).
Variable Group 1
Mean LV thickness b 12 mm
(n = 47)
Group 2
CHF(−) and BNP b 100 pg/mL
(n = 35)
Group 3
CHF(+) or BNP ≥ 100 pg/mL
(n = 41)
Age, year 44 ± 13 62 ± 12* 63 ± 12*
Gender (male/female), n 22/25 26/9 19/22
Type of mutation
V30M/non-V30M
47/0 34/1 (S50R) 33/8 [D38A (3), S50I (1), E54K (1),
E42G(1), S50R (1), H88R (1)]
Systolic blood pressure, mm Hg 112 ± 10 120 ± 19 107 ± 17§
Diastolic blood pressure, mm Hg 71 ± 10 78 ± 13# 65 ± 12#,†
Heart rate, bpm 70 ± 13 61 ± 11‖ 61 ± 11‡
Left atrial diameter, cm 3.33 ± 0.47 4.09 ± 0.67⁎ 4.24 ± 0.70⁎
Left atrial volume max, mL 48 ± 18 68 ± 28‖ 81 ± 28⁎,⁎⁎
Left atrial volume min, mL 21 ± 10 34 ± 20# 54 ± 27⁎,†
Left atrial emptying fraction, % 56 ± 9 52 ± 9 36 ± 14⁎,†
LV end-diastolic diameter, cm 4.35 ± 0.42 4.37 ± 0.46 4.30 ± 0.48
LV end-systolic diameter, cm 2.52 ± 0.38 2.69 ± 0.35 2.80 ± 0.49‖
LV fractional shortening, % 42.2 ± 6.9 38.5 ± 5.5 34.9 ± 7.1⁎,§
LV thickness (septum), cm 1.00 ± 0.15 1.63 ± 0.30⁎ 1.92 ± 0.39⁎,†
LV thickness (posterior), cm 0.92 ± 0.16 1.38 ± 0.24⁎ 1.66 ± 0.32⁎,†
LV end-diastolic volume, mL 50 ± 15 54 ± 11 56 ± 16
LV end-systolic volume, mL 19 ± 6 21 ± 5 25 ± 9‡
LV ejection fraction, % 62 ± 5 61 ± 5 55 ± 10‡,§
Plasma BNP, pg/mL 30.3 ± 25.0 48.0 ± 24.6 315.5 ± 282.4⁎,†
⁎ P b 0.0001 vs. group 1.
† P b 0.0001 vs. group 2.
‡ P b 0.001 vs. group 1.
§ P b 0.01 vs. group 2.
‖ P b 0.01 vs. group 1.
# P b 0.05 vs. group 1.
⁎⁎ P b 0.05 vs. group 2.
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3 than that in the other 2 groups.
3.2. Two-dimensional echocardiography
LAdiameterwas greater in groups 2 and 3 than that in group 1.Max-
imum and minimum LA volumes were larger in group 2 than group 1,
and larger in group 3 than that in group 2. LA emptying fraction in
group 3 was signiﬁcantly lower than that in the other 2 groups. The
LV end-diastolic diameter and volume showed no signiﬁcant difference
among the 3 groups, but the LV end-systolic diameter and volumewere
greater in group 3 than those in the other 2 groups, and the LV fractional
shortening and ejection fraction were smaller in group 3 than those in
the other 2 groups.
3.3. Standard Doppler ﬂow and pulsed tissue Doppler
Transmitral ﬂow, pulmonary venous ﬂow, and LV outﬂow tract ﬂow
data are shown in Table 2. Patients in group 3 showed abnormal values
in transmitralﬂow, pulmonary venous ﬂow parameters, and isovolumic
contraction time compared to those in groups 1 and 2. Patients in group
2 showed smaller values of peak E velocity of transmitral ﬂow, but
greater values of peak A wave, deceleration time of transmitral ﬂow,
isovolumic relaxation time, and ejection time compared to those in
the other 2 groups. Patients in group 3 showed smaller values of
transmitral peak A-wave velocity, peak S, and peak A velocity of pulmo-
nary venous ﬂow compared to those in groups 1 and 2.
Pulsed tissue Doppler velocity of the mitral annulus (s′, e′, and a′)
and E/e′ at the septal and lateral walls was smaller in group 2 than
that in group 1, and smaller in group 3 than that in group 2. E/e′ ratio
at the septal and lateral walls was greater in group 2 than that in
group 1, and greater in group 3 than that in group 2.
3.4. LV rotational measurements
Rotation and rotation rate (S, E, A) in basal LV did not show signiﬁ-
cant intergroup differences (Table 3). The rotation in mid-LV showedsmaller values in groups 2 and 3 than that in group 1. There were no
signiﬁcant differences in rotation rate (S, E, A) in mid-LV among the 3
groups. The rotation and rotation rate (S) in apical LV were lower in
group 3 than those in group 1, and rotation rate (E) in groups 2 and
3 was less than that in group 1. LV torsion was smaller in group 3 than
that in group 1, and torsion rate (S, A) was smaller in group 3 than
that in the other 2 groups. The rotation rate (E) was smaller in group
2 than that in group 1.
3.5. Global left ventricular strain and strain rate
GLS and systolic strain rate (S)were superior in detectingdifferences
among the 3 groups (Table 4). The values of early diastolic longitudinal
strain rate (E) in group 2 were smaller than those in group 1, whereas
those in group 3 were similar to those in group 2. The values of late
diastolic longitudinal strain rate (A) in group 2 were similar to those
in group 1, and were lower in group 3 than those in the other 2 groups.
The values of global circumferential strain, systolic strain rate (S), and
early diastolic strain rate (E) in group 2 were smaller than those in
group 1, whereas those in group 3 were preserved as those in group 2.
These tendencieswere observed at all (basal,mid-, and apical) LV levels.
On the other hand, the values of global late diastolic strain rate (A) in
group 2 were similar to those in group 1, whereas those in group 3
were lower than those in the other 2 groups. The values of mean radial
strain, and early diastolic strain rate (E) were superior in detecting
differences among the3 groups at basal LV,whereas therewas nodiffer-
ence in radial strain in apical LV. The value ofmean radial strain rate (S),
(A) separates group 3 from groups 1 and 2 in basal, mid-, and apical LV.
3.6. Segmental left ventricular strain and strain rate
Fig. 1A–C show segmental LV longitudinal strain and strain rate
calculated from the septal, lateral, inferior, anterior, posterior, and
anteroseptal walls in the basal, mid, and apical left ventricle. Strain
and strain rate documented that an increased wall thickness was asso-
ciated with a decrease in systolic parameters in group 2 (no CHF) at
the base and mid-LV. In addition, group 3 had greater abnormalities of
Table 2
Doppler ﬂow and pulsed tissue Doppler data (mean ± SD).
Variable Group 1 (n = 47) Group 2 (n = 35) Group 3 (n = 41)
Transmitral ﬂow peak E velocity, m/s 0.84 ± 0.22 0.69 ± 0.24# 0.85 ± 0.21§
Transmitral ﬂow peak A velocity, m/s 0.71 ± 0.17 0.83 ± 0.19# 0.61 ± 0.25#,†
Transmitral ﬂow peak E/A 1.23 ± 0.43 0.89 ± 0.54 1.84 ± 1.34‖,†
Deceleration time of transmitral ﬂow, ms 203 ± 49 281 ± 75⁎ 232 ± 68§
Transmitral ﬂow A duration, ms 149 ± 22 169 ± 24‖ 164 ± 30‖
Pulmonary venous ﬂow peak S velocity, m/s 0.53 ± 0.13 0.56 ± 0.15 0.43 ± 0.20‖,§
Pulmonary venous ﬂow peak D velocity, m/s 0.45 ± 0.09 0.38 ± 0.14 0.57 ± 0.19‡,†
Pulmonary venous ﬂow peak A velocity, m/s 0.30 ± 0.06 0.34 ± 0.13 0.26 ± 0.13§
Pulmonary venous ﬂow peak D/S 0.90 ± 0.25 0.80 ± 0.73 1.86 ± 1.59⁎,†
Pulmonary venous ﬂow D velocity deceleration time, ms 283 ± 287 339 ± 123 254 ± 79
Pulmonary venous ﬂow A duration, ms 157 ± 24 184 ± 41‖ 184 ± 34⁎
Left ventricular outﬂow tract peak velocity, m/s 0.98 ± 0.16 0.95 ± 0.17 1.00 ± 0.20
Left ventricular outﬂow tract mean velocity, m/s 0.64 ± 0.10 0.64 ± 0.12 0.66 ± 0.14
Left ventricular outﬂow tract velocity time integral, cm 19.3 ± 3.9 20.3 ± 3.4 19.5 ± 4.3
Isovolumic contraction time, ms 82 ± 17 94 ± 21 109 ± 29⁎,§
Isovolumic relaxation time, ms 87 ± 20 122 ± 31‡ 109 ± 46‖
Ejection time, ms 294 ± 38 317 ± 39# 294 ± 31§
Tissue Doppler imaging (peak systolic: s′, septum), cm/s 6.45 ± 1.33 5.05 ± 1.05⁎ 3.63 ± 1.31⁎,†
Tissue Doppler imaging (peak early diastolic: e′, septum), cm/s 6.43 ± 2.04 3.10 ± 1.14⁎ 2.40 ± 0.90⁎,⁎⁎
Tissue Doppler Imaging (peak late diastolic: a′, septum), cm/s 6.45 ± 1.40 5.84 ± 1.26 3.25 ± 1.91⁎,†
Tissue Doppler Imaging (peak systolic: s', lateral wall), cm/s 7.78 ± 2.10 5.76 ± 1.73⁎ 4.27 ± 1.52⁎,§
Tissue Doppler Imaging (peak early diastolic: e′, lateral wall), cm/s 8.77 ± 2.65 4.63 ± 1.72⁎ 3.34 ± 1.35⁎,⁎⁎
Tissue Doppler Imaging (peak late diastolic a′, lateral wall), cm/s 5.99 ± 1.56 5.72 ± 1.30 3.07 ± 1.66⁎,†
E/e′ (septum) 14.0 ± 5.1 24.1 ± 9.2‖ 39.8 ± 19.6⁎,†
E/e′ (lateral wall) 10.2 ± 3.7 17.0 ± 8.4‖ 29.4 ± 12.9⁎,†
⁎ P b 0.0001 vs group 1.
† P b 0.0001 vs group 2.
‡ P b 0.001 vs group 1.
§ P b 0.01 vs group 2.
‖ P b 0.01 vs group 1.
# P b 0.05 vs group 1.
⁎⁎ P b 0.05 vs group 2.
Table 4
Global left ventricular strain imaging data.
Variable Group 1
(n = 47)
Group 2
(n = 35)
Group 3
(n = 41)
Global longitudinal strain (%) −17.3 ± 2.3 −13.3 ± 2.3⁎ −9.9 ± 3.3⁎,†
Strain rate (S)(s−1) −1.04 ± 0.21 −0.75 ± 0.14⁎ −0.58 ± 0.19⁎,§
Strain rate (E) (s−1) 1.23 ± 0.33 0.60 ± 0.19⁎ 0.54 ± 0.15⁎
Strain rate (A) (s−1) 0.80 ± 0.23 0.81 ± 0.25 0.45 ± 0.29⁎,†
Basal global circ. strain (%) −19.5 ± 4.4 −16.5 ± 4.1‖ −16.0 ± 4.1⁎
Strain rate (S) (s−1) −1.32 ± 0.29 −1.19 ± 0.34 −1.07 ± 0.27⁎
Strain rate (E) (s−1) 1.68 ± 0.62 0.99 ± 0.43⁎ 0.91 ± 0.34⁎
Strain rate (A) (s−1) 0.79 ± 0.31 0.77 ± 0.31 0.52 ± 0.43‡,#
4 J. Koyama et al. / IJC Heart & Vasculature 9 (2015) 1–10strain and peak systolic strain rate (S) than those in group 2 at all sites in
basal and mid-LV. Contrary to the ﬁndings for basal and mid-LV, apical
longitudinal strain in lateral, anterior, and posteriorwallswas preserved
similarly to those in groups 1 and 2.
Fig. 2A–C show circumferential and radial strain/strain rate calculat-
ed from anteroseptal, anterior, lateral, posterior, inferior, and septal
walls in basal, mid, and apical LV. In the basal LV, circumferential strain
(other than in lateral and posterior walls) and strain rate (S, E, and A) in
all 6 segments in group 3 showed lower values than in the other 2
groups. Furthermore, strain rate (S and A) in group 2 were preserved
similarly to those in group 1. These tendencies were observed in theTable 3
Left ventricular (LV) rotational data.
Variable Group 1
(n = 47)
Group 2
(n = 35)
Group 3
(n = 41)
Basal LV rotation (°) −2.0 ± 4.4 −3.7 ± 3.9 −2.1 ± 2.8
Basal rotation rate (S) (°/s) −20.4 ± 61.9 −29.7 ± 44.6 −17.0 ± 28.9
Basal rotation rate (E) (°/s) 34.4 ± 47.5 37.4 ± 47.5 15.6 ± 25.0
Basal rotation rate (A) (°/s) 20.8 ± 42.7 25.8 ± 30.3 12.9 ± 20.3
Mid-LV rotation (°) 2.5 ± 4.7 −0.3 ± 4.6‡ 0.3 ± 3.3‡
Mid- rotation rate (S) (°/s) 16.9 ± 52.5 −0.5 ± 51.0 −1.0 ± 34.4
Mid- rotation rate (E) (°/s) −17.0 ± 63.2 2.9 ± 55.8 −0.8 ± 32.5
Mid- rotation rate (A) (°/s) −10.8 ± 41.0 7.1 ± 46.9 2.9 ± 21.1
Apical LV rotation (°) 7.4 ± 4.9 5.3 ± 3.8 5.0 ± 3.5†
Apical rotation rate (S) (°/s) 64.3 ± 48.3 49.3 ± 35.0 39.3 ± 26.3†
Apical rotation rate (E) (°/s) −67.6 ± 46.9 −45.1 ± 42.1‡ −36.7 ± 26.0⁎
Apical rotation rate (A) (°/s) −26.1 ± 38.7 −24.0 ± 34.3 −14.6 ± 18.3
LV torsion (°) 10.0 ± 5.3 8.7 ± 4.5 7.0 ± 3.3†
LV torsion rate (S) (°/s) 79.1 ± 40.9 73.8 ± 38.8 53.7 ± 16.2⁎,§
LV torsion rate (E) (°/s) −93.9 ± 56.4 −61.7 ± 54.7† −49.5 ± 21.2⁎
LV torsion rate (A) (°/s) −42.4 ± 34.2 −42.0 ± 41.6 −25.3 ± 17.5†,‖
⁎ P b 0.0001 vs. group 1.
† P b 0.01 vs. group 1.
‡ P b 0.05 vs. group 1.
§ P b 0.01 vs. group 2.
‖ P b 0.05 vs. group 2.
Mid-global circ. strain (%) −20.1 ± 4.0 −16.5 ± 6.4‖ −16.6 ± 3.7‡
Strain rate (S) (s−1) −1.33 ± 0.35 −1.11 ± 0.30‖ −1.06 ± 0.24⁎
Strain rate (E) (s−1) 1.50 ± 0.48 1.02 ± 0.42⁎ 0.96 ± 0.30⁎
Strain rate (A) (s−1) 0.86 ± 0.42 0.81 ± 0.37 0.53 ± 0.36⁎,#
Apical global circ. strain (%) −21.9 ± 5.8 −18.5 ± 4.6‖ −18.3 ± 4.8‖
Strain rate (S) (s−1) −1.54 ± 0.40 −1.23 ± 0.33‡ −1.13 ± 0.28⁎
Strain rate (E) (s−1) 1.77 ± 0.60 1.17 ± 0.37⁎ 1.21 ± 0.46⁎
Strain rate (A) (s−1) 0.93 ± 0.44 1.14 ± 0.53 0.54 ± 0.38⁎,†
Basal mean radial strain (%) 60.0 ± 2.5 43.3 ± 3.0⁎ 31.0 ± 2.0⁎,#
Strain rate (S) (s−1) 2.19 ± 0.80 2.01 ± 0.75 1.45 ± 0.49⁎,§
Strain rate (E) (s−1) −2.39 ± 0.11 −1.71 ± 0.13‡ −1.07 ± 0.40⁎,§
Strain rate (A) (s−1) −1.74 ± 1.04 −1.53 ± 0.73 −0.90 ± 0.60⁎,§
Mid-mean radial strain (%) 61.7 ± 25.4 42.7 ± 15.3⁎ 36.3 ± 18.3⁎
Strain rate (S) (s−1) 2.19 ± 1.58 1.98 ± 0.85 1.53 ± 0.54‖
Strain rate (E) (s−1) −2.55 ± 1.24 −1.64 ± 0.84⁎ −1.26 ± 0.58⁎
Strain rate (A) (s−1) −1.58 ± 0.97 −1.65 ± 0.83 −0.96 ± 0.62⁎,†
Apical mean radial strain (%) 41.2 ± 23.0 37.5 ± 17.0 36.3 ± 19.2
Strain rate (S) (s−1) 1.82 ± 0.79 1.95 ± 0.71 1.48 ± 0.69#,⁎⁎
Strain rate (E) (s−1) −2.26 ± 0.98 −1.73 ± 0.66‖ −1.34 ± 0.68⁎,††
Strain rate (A) (s−1) −1.14 ± 0.66 −1.66 ± 0.81‖ −0.91 ± 0.74†
⁎ P b 0.0001 vs group 1.
† P b 0.0001 vs group 2.
‡ P b 0.001 vs group 1.
§ P b 0.001 vs group 2.
‖ P b 0.01 vs group 1.
# P b 0.01 vs group 2.
⁎⁎ P b 0.05 vs group 1.
†† P b 0.05 vs group 2.
5J. Koyama et al. / IJC Heart & Vasculature 9 (2015) 1–10mid- and apical LV. Contrary to the ﬁnding for circumferential strain,
radial strain and strain rate (E) in all 6 basal LV segments clearly
discriminated the 3 groups. In the mid-LV, radial strain rate (S, and
A) clearly discriminated group 3 from those in groups 1 and 2, but radialFig. 1. Longitudinal strain, and strain rate in basal, mid-, and apical left ventricle at the septal, l
amyloid; group 2, cardiac amyloid without CHF; group 3, CHF(+). *P b 0.0001 vs. group 1; †P
#P b 0.01 vs. group 2; **P b 0.05 vs. group 1; ††P b 0.05 vs. group 2; NS, not signiﬁcant.strain and strain rate (E)were similar in groups 2 and 3. In the apical LV,
radial strain rate (S, and A) in group 3 showed lower values than those
in groups 1 and 2, although radial strain did not differ signiﬁcantly
among the 3 groups.ateral (A), inferior, anterior (B), posterior, and anteroseptal (C) walls. Group 1, noncardiac
b 0.0001 vs. group 2; ‡P b 0.001 vs. group 1; §P b 0.001 vs. group 2; ‖P b 0.01 vs. group 1;
Fig. 1 (continued).
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As shown in Table 5, in the discontinued (due to transient renal
dysfunction) diﬂunisal group (n = 7), the LV end diastolic volume
was statistically decreased, the global longitudinal strain and the mean
basal longitudinal strain had shown a tendency to decrease, and the
mean mid-longitudinal strain, mean mid- and apical radial strains had
been signiﬁcantly decreased after 1 year follow-up. In contrast, the
diﬂunisal treatment group (n = 34) showed signiﬁcant improvement
in the apical LV rotation and torsionwithout deterioration in the longitu-
dinal, and radial strains after 1 year follow-up. Among 41 patients, no
patients died during the 1 year follow-up period.
3.8. Reproducibility of measurements
Reproducibility of measurements is summarized in Table 6. Intra-
observer and interobserver agreement for longitudinal, circumferential,
radial strain and rotation/torsion measurements was excellent, but
intraobserver and interobserver agreement for longitudinal, circumfer-
ential, and radial strain rate was poor. The coefﬁcients of variation for
intraobserver and interobserver comparisons were less than 10%.
4. Discussion
To the best of our knowledge, this study includes the maximum
number of patients with ATTRm who were evaluated by speckle track-
ing echocardiography. We also clarify ﬁrst the favorable effect of
diﬂunisal on cardiac function in patients who were not indicated for
liver transplantation. The main ﬁndings of this study were 1) ATTRm
cardiac amyloidosis has a speciﬁc pattern of LV longitudinal strain,
characterized by worse longitudinal strain in the basal and mid-LV
with relative sparing of the apex, as we previously reported for AL car-
diac amyloidosis [14,26]; 2) the radial strain shows a similar pattern
to the LV longitudinal strain, i.e., a speciﬁc pattern of LV radial straincharacterized by worse radial strain in the basal and mid-LV, with rela-
tive sparing of the apex; 3) circumferential strain is relatively preserved
until the presence of CHF; 4) LV torsion is not increased as in true LV
hypertrophy [31,32], but is relatively preserved until the onset of
overt CHF signs; 5) diﬂunisal could be used safely even in severe cardiac
amyloidosis like group 3; and 6) the follow-up study after diﬂunisal
treatment suggested that the STE could detect subtle changes in cardiac
function.
The mechanism of the speciﬁc pattern of LV longitudinal and radial
strain and preserved circumferential strain may be explained by the
amyloid deposition pattern in ATTRm as follows:
• Cardiac magnetic resonance with delayed gadolinium enhancement
has demonstrated that the deposition of amyloid ﬁbrils occurs from
the endocardial side to the epicardial side [33].
• In the LV endocardial layer, there exist longitudinally oriented myo-
cardial ﬁbers, which contribute to LV longitudinal and inner LV layer
radial function. Therefore, amyloid deposition in the endocardial
layer might cause longitudinal systolic dysfunction, which should
lead to worse longitudinal and radial LV strain.
• On the other hand, LV circumferential ﬁber exists in the mid-layer
of LV myocardium. Therefore, circumferential LV shortening might
be preserved until amyloid inﬁltration progresses to the mid-layer
in advanced cardiac amyloidosis.
4.1. Left ventricular torsion in amyloidosis
Previous studies indicated that in patients with true LV hypertrophy,
LV torsion values were signiﬁcantly increased compared to normal
subjects [31]. Contrary to the ﬁndings in true myocardial hypertrophy,
LV torsion valueswere signiﬁcantly decreased in advanced stages of car-
diac amyloidosis. Subendocardial rotation was found to be higher than
subepicardial rotation [32]. Subendocardial-dominant deposition of
amyloid protein might decrease the subendocardial-dominant rotation.
However, the larger moment arm of the subepicardial ﬁbers dominates
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clockwise and clockwise directions, respectively [34]. This may account
for the relative sparing of LV torsion in the early to middle stages of
cardiac amyloidosis. However, once amyloid inﬁltration affects the
subepicardial layer in the advanced stage, LV torsion will decrease, as
seen in patients with CHF.Fig. 2. Circumferential and radial strain/strain rate on basal (A), mid (B), and apical (C) left vent
and P-values are the same those in Fig. 1.4.2. Left atrial function in cardiac amyloidosis
We also evaluated the LA emptying fraction, which have not been
described in previous reports. The LA emptying fraction decreases in
CHF, whereas it is preserved in patients with LVH without CHF. This
ﬁnding partially explains the higher transmitral A-wave velocity andricle at the anteroseptal, anterior, lateral, posterior, inferior, and septalwalls. Abbreviations
Fig. 2 (continued).
Table 5
Serial observation 1 year after initial echocardiographic examination.
Pre-diﬂunisal
(n = 34)
1 year after
diﬂunisal
P Treatment cessation due to newly developed
renal dysfunction after diﬂunisal (n = 7)
Treatment cessation
1 year
P
Age, year 57 ± 16 – – 54 ± 17 – –
Gender (M/F), n 23/11 – – 5/2 – –
V30M/non-V30M 27/7 – – 7/0 – –
Group 1/2/3 12/7/15 – – 3/1/3
SBP, mm Hg 112 ± 14 111 ± 14 0.87 109 ± 11 111 ± 18 0.49
DBP, mm Hg 70 ± 12 69 ± 11 0.57 67 ± 5 72 ± 6 0.10
Heart rate, bpm 68 ± 11 64 ± 12 0.05 70 ± 8 73 ± 14 0.49
BUN, mg/dl 14.1 ± 4.9 15.8 ± 5.1 0.044 20.7 ± 9.0 24.1 ± 9.5 0.20
Creatinine, mg/dl 0.78 ± 0.21 0.83 ± 0.22 0.019 0.94 ± 0.35 0.95 ± 0.34 0.86
IVSThd, cm 1.59 ± 0.54 1.59 ± 0.53 0.94 1.75 ± 0.75 1.80 ± 0.64 0.58
LVPWThd, cm 1.33 ± 0.39 1.38 ± 0.41 0.16 1.49 ± 0.52 1.56 ± 0.51 0.12
TMF-E/A 1.15 ± 0.69 1.27 ± 0.68 0.18 1.69 ± 1.33 1.96 ± 2.1 0.54
TMF-E-DT, ms 235 ± 67 238 ± 68 0.79 188 ± 49 204 ± 50 0.62
PVF-D/S 0.98 ± 0.52 1.10 ± 0.62 0.08 1.69 ± 1.46 1.45 ± 0.97 0.54
LVOT-VTI, cm 20.2 ± 3.4 19.9 ± 3.4 0.65 15.5 ± 4.0 14.5 ± 3.4 0.44
LVEDV, mL 50 ± 16 49 ± 15 0.65 50 ± 8 40 ± 9 0.04
LVESV, mL 21 ± 8 20 ± 8 0.39 23 ± 8 20 ± 10 0.25
LVEF, % 60 ± 8 61 ± 7 0.43 55 ± 11 53 ± 16 0.46
BNP, pg/mL 123 ± 150 148 ± 156 0.13 200 ± 207 335 ± 365 0.26
GLS (AFI), % −13.1 ± 3.8 −12.9 ± 4.0 0.45 −13.0 ± 6.2 −8.7 ± 5.4 0.07
Mean basal LS, % −12.1 ± 5.8 −12.3 ± 5.6 0.52 −14.8 ± 7.1 −9.7 ± 5.4 0.07
Mean mid LS, % −13.7 ± 4.3 −13.8 ± 4.2 0.90 −14.6 ± 6.0 −10.0 ± 5.0 0.052
Mean apical LS, % −14.6 ± 3.4 −14.2 ± 3.3 0.55 −12.8 ± 4.8 −10.4 ± 4.3 0.29
Basal GCS, % −16.6 ± 3.6 −17.1 ± 3.7 0.49 −17.1 ± 5.7 −16.4 ± 6.0 0.53
Mid GCS, % −17.2 ± 3.6 −16.9 ± 3.9 0.68 −15.5 ± 6.2 −16.9 ± 6.7 0.22
Apical GCS, % −17.9 ± 5.2 −18.7 ± 4.6 0.12 −18.5 ± 6.8 −16.6 ± 8.7 0.31
Mean basal RS, % 44 ± 21 40 ± 19 0.21 48 ± 25 37 ± 25 0.13
Mean mid RS, % 46 ± 21 43 ± 20 0.46 50 ± 28 34 ± 21 0.04
Mean apical RS, % 41 ± 20 37 ± 20 0.12 42 ± 28 32 ± 24 0.0077
Basal LV rotation (°) −3.0 ± 3.7 −2.6 ± 4.2 0.68 −3.0 ± 2.4 −2.1 ± 2.8 0.52
Apical LV rotation (°) 4.8 ± 2.7 7.3 ± 3.6 0.0012 5.3 ± 4.4 8.7 ± 4.3 0.20
LV torsion (°) 7.5 ± 3.4 9.7 ± 5.1 0.037 8.4 ± 3.6 11.5 ± 4.9 0.18
No treatment, discontinued diﬂunisal because of deterioration in renal function after diﬂunisal treatment; IVSThd, LV thickness (septum); LVPWThd, LV thickness (posterior wall); TMF,
transmitral ﬂow; DT, deceleration time; PVF, pulmonary venous ﬂow; LVOT, left ventricular outﬂow tract; VTI, velocity time integral; LVEDV, LV end-diastolic volume; LVESV, LV end-
systolic volume; LVEF, LV ejection fraction; GLS, global longitudinal strain; AFI, automated function imaging; LS, longitudinal strain; GCS, global circumferential strain and RS, radial strain.
Bold means statistically signiﬁcance during 1 year follow-up.
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Table 6
Reproducibility of measurements.
Intraobserver agreement
(mean ± 1.96 SD) (%)
Coefﬁcient variation for
intraobserver comparisons (%)
Interobserver agreement
(mean ± 1.96 SD) (%)
Coefﬁcient variation for
interobserver comparisons (%)
Longitudinal strain 0.14 ± 1.56 5.8 0.08 ± 1.55 7.0
Circumferential strain 0.25 ± 2.0 6.1 2.6 ± 7.2 7.0
Radial strain 0.21 ± 4.9 6.2 2.2 ± 9.9 7.1
Rotation 0.02 ± 3.1 3.6 3.1 ± 3.4 9.6
Torsion 0.14 ± 2.2 9.0 2.7 ± 6.1 7.0
Longitudinal SR 0.9 ± 8.7 7.8 0.37 ± 13.8 9.8
Circumferential SR 0.3 ± 12.9 9.8 1.3 ± 16.4 9.2
Radial SR 0.22 ± 11.3 8.7 1.9 ± 22.3 8.5
SR, strain rate.
9J. Koyama et al. / IJC Heart & Vasculature 9 (2015) 1–10the compensatory mechanism of LA function in group 2 compared to
group 1.
4.3. Limitations
Cardiac involvement was deﬁned as a mean value of LV thickness
N12 mm in patients with ATTRm amyloidosis conﬁrmed by a biopsy
from any site. Thus, many patients were diagnosed as having cardiac
amyloidosis without endomyocardial biopsy. However, on the basis of
autopsy studies, it generally is accepted that the echocardiographic
ﬁnding of LV thickening in the absence of diseases associated with LV
hypertrophy is highly speciﬁc for the ﬁnding of cardiac amyloidosis at
biopsy or autopsy [35]. Furthermore, to ensure deﬁnite cardiac involve-
ment by amyloid ﬁbrils, we used the combined criteria with mean LV
wall thickness and 99mTc-PYP scintigraphy. This method is reported
to be sensitive in detecting cardiac amyloid involvement, andmay assist
in discriminating group 1 from groups 2 and 3.
The follow-up period was too short to evaluate the [36] effect of
diﬂunisal treatment on cardiac function, and improvement in apical ro-
tation and torsion without deterioration in multidirectional strains is a
weak end point. Further longer follow-up study is required to conﬁrm
the results.
5. Conclusions
Transthyretin-associated cardiac amyloidosis is characterized by a
progressive impairment of longitudinal and radial LV function at a time
when circumferential shortening and LV torsion remain unchanged.
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